Compare Ascendis Pharma A/S (ASND) vs Cadence Design Systems Inc (CDNS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Cadence Design Systems Inc — how do they compare? Ascendis Pharma A/S trades at $270.45 (market cap $17.74B), while Cadence Design Systems Inc trades at $390.31 (market cap $105.96B). The key difference: Cadence Design Systems Inc is far larger — about 6× Ascendis Pharma A/S's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Cadence Design Systems Inc nearer its low. Which is the better fit depends on your goals.
| ASND | CDNS | |
|---|---|---|
Market Cap | $17.74B | $105.96B |
Sector | Health | Technology |
52-Week High | $277.18 | $416.39 |
52-Week Low | $163.32 | $265.66 |
Enterprise Value | $18.11B | $107.64B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Cadence Design Systems (CDNS) trades at $384.17, down 0.46% on the day, with strong technical momentum indicated by bullish moving averages. The company demonstrates robust fundamentals with consistent revenue growth from $3.6B in 2022 to $5.3B in 2025, and has beaten earnings estimates for three consecutive quarters. Analyst sentiment remains overwhelmingly positive with 83.87% buy ratings and a $395.88 consensus price target, representing 3% upside potential.
The outlook for CDNS remains favorable given its strategic position in semiconductor design software and AI-driven demand, though elevated valuation ratios (P/E 89.55, P/S 18.99) warrant caution. Key risks include semiconductor cycle volatility and competitive pressures, but strong cash flow generation and institutional support provide stability for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Cadence Design Systems Inc
Cadence Design Systems is a provider of electronic design automation software, intellectual property, and system design and analysis products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. Cadence offers a portfolio of design IP, as well as system design and analysis products, which enable system-level analysis and verification solutions. Cadence's comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers, alongside secular digitalization of various end markets, benefits EDA vendors like Cadence.
Read more on CDNS →
